🔗 Permalink

Inventor profile of:

John C. Byrd

City:

Columbus, Ohio

Country:

United States

Published Applications:

Last publication date:

2026-03-12

Top Assignees for applications by John C. Byrd

The entities that hold a legal rights for patent applications filed by inventor Byrd John C.:

THE OHIO STATE UNIVERSITY 6 Columbus, OH United States
PHARMACYCLICS, LLC. 5 Sunnyvale, CA United States
IMMUNOMEDICS, INC. 3 Morris Plains, NJ United States
Pharmacyclics, Inc 2 Sunnyvale, CA United States
Ohio State Innovation Foundation 2 Columbus, OH United States
Hendrix College 2 Conway, AR United States
THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION 2 Columbus, OH United States

Recent patent applications by Byrd John C.

John C. Byrd from Columbus, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2026-03-12

US20260069581A1

Human necessities

METHODS AND COMPOSITIONS FOR CANCER THERAPY

#2 | 2025-11-13

US20250345335A1

Human necessities

METHODS OF TREATING AND PREVENTING GRAFT VERSUS HOST DISEASE

#3 | 2024-10-03

US20240325373A1

Human necessities

METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD47-SIRPA THERAPEUTIC AGENT

#4 | 2024-09-05

US20240294477A1

Chemistry; metallurgy

METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE

#5 | 2024-09-05

US20240293408A1

Human necessities

METHODS OF TREATING AND PREVENTING GRAFT VERSUS HOST DISEASE

#6 | 2024-01-18

US20240018108A1

Chemistry; metallurgy

METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE

#7 | 2023-09-28

US20230303710A1

Chemistry; metallurgy

METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT

#8 | 2023-05-25

US20230158030A1

Human necessities

METHODS AND COMPOSITION FOR TREATMENT OF COVID-19 ILLNESS REQUIRING HOSPITALIZATION

#9 | 2023-04-06

US20230109418A1

Chemistry; metallurgy

COMPOSITIONS FOR USE FOR THE INHIBITION OF DIHYDROOROTATE DEHYDROGENASE

#10 | 2023-03-30

US20230097340A1

Human necessities

METHODS OF TREATING AND PREVENTING GRAFT VERSUS HOST DISEASE

#11 | 2023-03-23

US20230089524A1

Chemistry; metallurgy

COMPOSITIONS FOR USE IN THE INHIBITION OF DIHYDROOROTATE DEHYDROGENASE

#12 | 2022-03-03

US20220064119A1

Chemistry; metallurgy

Methods and compositions for inhibition of dihydroorotate dehydrogenase

#13 | 2021-08-19

US20210253531A1

Chemistry; metallurgy

Methods and compositions for inhibition of dihydroorotate dehydrogenase

#14 | 2021-04-29

US20210121463A1

Human necessities

METHODS OF TREATING AND PREVENTING GRAFT VERSUS HOST DISEASE

#15 | 2020-05-14

US20200147084A1

Human necessities

TEC FAMILY KINASE INHIBITOR ADJUVANT THERAPY

#16 | 2020-01-09

US20200009148A1

Human necessities

Methods of treating and preventing graft versus host disease

#17 | 2019-07-04

US20190203297A1

Chemistry; metallurgy

PHOSPHOLIPASE C GAMMA 2 AND RESISTANCE ASSOCIATED MUTATIONS

#18 | 2018-03-22

US20180078555A1

Human necessities

Methods of treating and preventing graft versus host disease

#19 | 2018-03-15

US20180071293A1

Human necessities

TEC FAMILY KINASE INHIBITOR ADJUVANT THERAPY

#20 | 2015-12-17

US20150361504A1

Chemistry; metallurgy

BIOMARKER FOR PREDICTING RESPONSE OF CLL TO TREATMENT WITH A BTK INHIBITOR

#21 | 2015-09-24

US20150267261A1

Chemistry; metallurgy

Phospholipase C gamma 2 and resistance associated mutations

#22 | 2015-04-30

US20150118209A1

Human necessities

Methods of treating and preventing graft versus host disease

#23 | 2014-12-18

US20140371241A1

Human necessities

TEC FAMILY KINASE INHIBITOR ADJUVANT THERAPY

#24 | 2014-05-15

US20140134265A1

Human necessities

TEC family kinase inhibitor adjuvant therapy

#25 | 2014-01-02

US20140005250A1

Human necessities

Compositions and methods for increasing drug efficacy in cancer

#26 | 2013-06-06

US20130142729A1

Human necessities

Anti-CD74 immunoconjugates and methods of use

#27 | 2012-05-31

US20120136063A1

Chemistry; metallurgy

FTY720-derived anticancer agents

#28 | 2012-04-26

US20120100068A1

Human necessities

Anti-CD74 immunoconjugates and methods of use

#29 | 2011-11-17

US20110280913A1

Human necessities

Methods and Compositions for Delivering Therapeutic Agents in the Treatment of B-Cell Related Disorders

#30 | 2011-02-03

US20110027798A1

Chemistry; metallurgy

Hybridization Quantitation Method for Modified Micro-RNA and -DNA Based Oligonucleotides

#31 | 2010-10-28

US20100272636A1

Human necessities

Anti-CD74 immunoconjugates and methods of use

#32 | 2005-01-11

US10403667

Treatment of patients with chronic lymphocytic leukemia

InventorID:

273733 ⎘